Broad chronic kidney disease labels can obscure distinct biology, complicating patient selection, progression assumptions and treatment-signal interpretation. In this sponsored episode of The Top Line, Will Hurth speaks with Dr. Ronen Schneider, medical director of renal genetics at Natera, about the business and development implications of moving toward genotype-defined kidney disease. 

Schneider explains how RenasightIQ connects genetic test results with clinical intake data, longitudinal laboratory measures and claims data from more than 300,000 patients. He discusses findings across FSGS and genetically defined glomerular disease, including differences in progression to end-stage kidney disease. 

The conversation translates those insights into considerations for drug-development teams: natural-history modeling, endpoint selection, prognostic enrichment, background therapy and patient recruitment. Schneider also outlines questions teams can apply to completed studies, ongoing trials and screening populations to evaluate genetic causes, placebo-arm progression and potential variation in treatment effect. Listen to the podcast to learn how real-world genetic data can help expose hidden heterogeneity and strengthen clinical development strategy. 

Broad chronic kidney disease labels can obscure distinct biology, complicating patient selection, progression assumptions and treatment-signal interpretation. In this sponsored episode of The Top Line, Will Hurth speaks with Dr. Ronen Schneider, medical director of renal genetics at Natera, about the business and development implications of moving toward genotype-defined kidney disease.&nbsp;
Schneider explains how RenasightIQ connects genetic test results with clinical intake data, longitudinal laboratory measures and claims data from more than 300,000 patients. He discusses findings across FSGS and genetically defined glomerular disease, including differences in progression to end-stage kidney disease.&nbsp;
The conversation translates those insights into considerations for drug-development teams: natural-history modeling, endpoint selection, prognostic enrichment, background therapy and patient recruitment. Schneider also outlines questions teams can apply to completed studies, ongoing trials and screening populations to evaluate genetic causes, placebo-arm progression and potential variation in treatment effect. Listen to the podcast to learn how real-world genetic data can help expose hidden heterogeneity and strengthen clinical development strategy.&nbsp;

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;